Understanding T cell responses to COVID-19 vaccines in patients with X-linked Agammaglobulinemia
Vaccine-induced SARS-CoV-2-specific T cell responses in patients with X-linked Agammaglobulinemia
['FUNDING_R21'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10762476
This study is looking at how well people with X-linked Agammaglobulinemia (XLA) respond to COVID-19 vaccines, especially focusing on their T cell responses, to see if the vaccines can still help their immune system fight the virus even though they can't make antibodies.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10762476 on ClinicalTrials.gov |
What this research studies
This research investigates how patients with X-linked Agammaglobulinemia (XLA), a primary immune deficiency, respond to SARS-CoV-2 vaccines, particularly focusing on T cell responses. Since XLA patients cannot produce antibodies due to their condition, the study aims to determine if the vaccines can still elicit effective T cell responses that may help control the virus. The research will involve monitoring these patients after vaccination to assess their immune responses and gather data that could inform future vaccination guidelines for individuals with similar immune deficiencies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with X-linked Agammaglobulinemia who are at least 21 years old.
Not a fit: Patients without primary immune deficiencies or those who do not have X-linked Agammaglobulinemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide critical insights into how to protect patients with XLA from COVID-19 through vaccination strategies.
How similar studies have performed: While research on T cell responses in other populations has shown promise, this specific investigation into XLA patients and COVID-19 vaccines is relatively novel.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DE PARIS, KRISTINA — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: DE PARIS, KRISTINA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.